These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
539 related articles for article (PubMed ID: 23792601)
1. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines. Eskander RN; Ji T; Huynh B; Wardeh R; Randall LM; Hoang B Int J Gynecol Cancer; 2013 Jul; 23(6):997-1005. PubMed ID: 23792601 [TBL] [Abstract][Full Text] [Related]
2. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis. Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863 [TBL] [Abstract][Full Text] [Related]
3. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667 [TBL] [Abstract][Full Text] [Related]
4. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008 [TBL] [Abstract][Full Text] [Related]
5. Statins inhibit tumor progression via an enhancer of zeste homolog 2-mediated epigenetic alteration in colorectal cancer. Ishikawa S; Hayashi H; Kinoshita K; Abe M; Kuroki H; Tokunaga R; Tomiyasu S; Tanaka H; Sugita H; Arita T; Yagi Y; Watanabe M; Hirota M; Baba H Int J Cancer; 2014 Dec; 135(11):2528-36. PubMed ID: 24346863 [TBL] [Abstract][Full Text] [Related]
6. Clinical and biological significance of Roh JW; Choi JE; Han HD; Hu W; Matsuo K; Nishimura M; Lee JS; Kwon SY; Cho CH; Kim J; Coleman RL; Lopez-Bernstein G; Sood AK Cancer Biol Ther; 2020; 21(2):147-156. PubMed ID: 31640461 [TBL] [Abstract][Full Text] [Related]
8. Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma. Liu L; Xu Z; Zhong L; Wang H; Jiang S; Long Q; Xu J; Guo J BJU Int; 2016 Feb; 117(2):351-62. PubMed ID: 24612432 [TBL] [Abstract][Full Text] [Related]
9. Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Krill L; Deng W; Eskander R; Mutch D; Zweizig S; Hoang B; Ioffe O; Randall L; Lankes H; Miller DS; Birrer M Gynecol Oncol; 2020 Feb; 156(2):423-429. PubMed ID: 31843273 [TBL] [Abstract][Full Text] [Related]
10. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and invasion in cervical cancer. Fang J; Zhang M; Li Q Am J Med Sci; 2011 Sep; 342(3):198-204. PubMed ID: 21629038 [TBL] [Abstract][Full Text] [Related]
11. MicroRNA-30d inhibits the migration and invasion of human esophageal squamous cell carcinoma cells via the post‑transcriptional regulation of enhancer of zeste homolog 2. Xie R; Wu SN; Gao CC; Yang XZ; Wang HG; Zhang JL; Yan W; Ma TH Oncol Rep; 2017 Mar; 37(3):1682-1690. PubMed ID: 28184915 [TBL] [Abstract][Full Text] [Related]
12. Enhancer of zeste homolog 2 blockade by RNA interference is implicated with inhibited proliferation, invasion and promoted apoptosis in endometrial carcinoma. Wang J; Ai Z; Chen J; Teng Y; Zhu J Oncol Lett; 2018 Jun; 15(6):9429-9435. PubMed ID: 29805666 [TBL] [Abstract][Full Text] [Related]
13. Polycomb repressor complex-2 is a novel target for mesothelioma therapy. Kemp CD; Rao M; Xi S; Inchauste S; Mani H; Fetsch P; Filie A; Zhang M; Hong JA; Walker RL; Zhu YJ; Ripley RT; Mathur A; Liu F; Yang M; Meltzer PA; Marquez VE; De Rienzo A; Bueno R; Schrump DS Clin Cancer Res; 2012 Jan; 18(1):77-90. PubMed ID: 22028491 [TBL] [Abstract][Full Text] [Related]
14. [Expression and relationship of Ezh2, Runx3 and caspase-3 in endometrial adenocarcinoma]. Guo ZL; Chen K; Wang XQ; Hu W Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):387-91. PubMed ID: 21914347 [TBL] [Abstract][Full Text] [Related]
15. [EZH2 gene silenced by siRNA suppresses the growth and invasion of endometrial carcinoma cells]. Leng L; Huang Q; Dong Y; Yu H; Tian Y; Peng G Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jun; 33(6):866-9. PubMed ID: 23803199 [TBL] [Abstract][Full Text] [Related]
16. Lentivirus-mediated RNA interference targeting the long noncoding RNA HOTAIR inhibits proliferation and invasion of endometrial carcinoma cells in vitro and in vivo. Huang J; Ke P; Guo L; Wang W; Tan H; Liang Y; Yao S Int J Gynecol Cancer; 2014 May; 24(4):635-42. PubMed ID: 24758900 [TBL] [Abstract][Full Text] [Related]
17. Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Eskander RN; Ali S; Dellinger T; Lankes HA; Randall LM; Ramirez NC; Monk BJ; Walker JL; Eisenhauer E; Hoang BH Int J Gynecol Cancer; 2016 Jan; 26(1):125-32. PubMed ID: 26397159 [TBL] [Abstract][Full Text] [Related]
18. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Li H; Cai Q; Godwin AK; Zhang R Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743 [TBL] [Abstract][Full Text] [Related]
19. Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma. Zhou J; Roh JW; Bandyopadhyay S; Chen Z; Munkarah AR; Hussein Y; Alosh B; Jazaerly T; Hayek K; Semaan A; Sood AK; Ali-Fehmi R Gynecol Oncol; 2013 Feb; 128(2):344-8. PubMed ID: 22871469 [TBL] [Abstract][Full Text] [Related]
20. EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastoma. Zhang J; Chen L; Han L; Shi Z; Zhang J; Pu P; Kang C Cancer Lett; 2015 Jan; 356(2 Pt B):929-36. PubMed ID: 25444902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]